Travere Therapeutics Insider Trades: Routine Sell‑to‑Cover Moves Show No Negative Outlook on Rare‑Disease Pipeline
Explore Travere’s insider “sell‑to‑cover” moves: routine tax‑cover trades, minimal price impact, and a net‑buying trend hinting at leadership confidence.
3 minutes to read